Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Condition: Neuroblastoma Interventions: Drug: Naxitamab monotherapy; Drug: GM-CSF; Drug: Irinotecan; Drug: Temozolomide; Drug: Naxitamab in combination therapy; Drug: GM-CSF with combination regimen; Drug: Sintilimab Sponsors: Sun Yat-sen University; Hainan General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Condition: Neuroblastoma Interventions: Drug: Naxitamab monotherapy; Drug: GM-CSF; Drug: Irinotecan; Drug: Temozolomide; Drug: Naxitamab in combination therapy; Drug: GM-CSF with combination regimen; Drug: Sintilimab Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials
MCT for the Harvard/UCSF ROBIN Center
Conditions: Glioma, Childhood Brainstem; Neuroblastoma Interventions: Radiation: External beam radiotherapy; Radiation: 131I-Metaiodobenzylguanidine (MIBG) Sponsors: Brigham and Women's Hospital; Dana-Farber Cancer Institute; National Cancer Institute (NCI); University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
Condition: Neuroblastoma Intervention: Biological: GD2 CAR T cells Sponsor: University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
